Medical device clinical trials represent a critical intersection of innovation, patient safety, and regulatory compliance in modern healthcare. The global medical device market, valued at approximately $512 billion in 2024, continues to expand at a compound annual growth rate of 5.8%, driven by technological advancements and aging populations worldwide. According to the U.S. Food and Drug Administration (FDA), medical devices range from simple tongue depressors to complex implantable pacemakers, each requiring rigorous clinical evaluation before market approval. This guide explores the systematic approach to conducting medical device clinical trials, from initial concept through regulatory submission and post-market surveillance.
What Are Medical Device Clinical Trials and Why Are They Essential?
Medical device clinical trials are structured research studies designed to evaluate the safety and effectiveness of medical devices in human subjects. Unlike pharmaceutical trials that assess drug compounds, these trials focus on mechanical, electronic, or biological instruments intended for diagnostic, therapeutic, or monitoring purposes. The FDA classifies medical devices into three categories based on risk: Class I (low risk), Class II (moderate risk), and Class III (high risk), with clinical trial requirements intensifying as risk levels increase.
The fundamental purpose of these trials extends beyond mere regulatory compliance. They establish evidence-based protocols for device usage, identify potential adverse events, and generate data that physicians rely upon when making treatment decisions. Recent analysis from the World Health Organization (WHO) indicates that approximately 2 million different kinds of medical devices are currently available globally, with an estimated 10,000 new device applications submitted annually to major regulatory bodies.
How Do Clinical Trial Requirements Impact Device Development?
A 2023 study published in the Journal of Medical Device Regulation found that 73% of Class III medical devices approved by the FDA between 2018-2023 required at least one pivotal clinical trial, with an average enrollment of 387 patients per study.
Data Interpretation: This data underscores the regulatory burden for high-risk devices nearly three-quarters require pivotal trials with substantial patient populations. The 387-patient average represents significant investment in time and resources, emphasizing why early-stage planning and efficient trial design are critical for device manufacturers pursuing Class III designations.
The clinical trial process serves multiple stakeholders. For manufacturers, successful trials provide the evidence necessary for regulatory approval and market differentiation. For healthcare providers, trial data informs clinical guidelines and best practices. For patients, these studies offer access to innovative treatments while ensuring that new devices meet rigorous safety standards before widespread adoption.
How Do Medical Device Clinical Trials Differ from Drug Trials?
Medical device clinical trials possess distinct characteristics that differentiate them from pharmaceutical studies. The primary distinction lies in the nature of the intervention: drugs produce systemic biochemical effects, while devices typically exert localized mechanical or electrical actions. This fundamental difference shapes trial design, endpoints, and regulatory requirements.
Comparative Analysis: Device Trials vs. Drug Trials
| Characteristic | Medical Device Trials | Drug Trials |
| Blinding Feasibility | Often challenging (surgical devices) | Generally achievable |
| Learning Curve Effect | Significant operator dependency | Minimal impact |
| Modification Potential | Can evolve during development | Fixed molecular structure |
| Placebo Control | Sham procedures ethically complex | Standard practice |
Table Explanation: This comparison highlights the fundamental methodological differences between device and drug trials. Device trials face unique challenges including operator skill variability, difficulty in blinding participants when devices are visible or implanted, and the ability to modify devices during development factors that require specialized trial design approaches.
How Does Operator Experience Impact Device Trial Outcomes?
Device trials frequently encounter the “learning curve” phenomenon, where outcomes improve as operators gain experience with the technology. A 2024 analysis in the New England Journal of Medicine demonstrated that surgical device performance improved by an average of 23% between the first 10 procedures and procedures 30-50 in pivotal trials. This operator-dependent variability necessitates careful protocol design, including operator training requirements and minimum procedure volume thresholds.
Another critical distinction involves the potential for device modifications during clinical development. While pharmaceutical compounds cannot be altered once a trial begins, device manufacturers may implement engineering changes to address safety concerns or improve performance. The FDA’s guidance on “Device Modifications Requiring a New Investigational Device Exemption Application” provides a framework for determining when such changes necessitate new approvals. These modifications can accelerate innovation but require meticulous documentation and regulatory communication.
What Regulatory Pathways Exist for Medical Device Clinical Trials?
Regulatory pathways for medical device clinical trials vary by jurisdiction, risk classification, and intended use. In the United States, the FDA operates the Investigational Device Exemption (IDE) system, which permits clinical studies of unapproved devices. According to FDA data, approximately 950 IDE applications are submitted annually, with approval rates ranging from 78% for traditional IDE studies to 94% for abbreviated IDE submissions for lower-risk devices.
The European Union follows the Medical Device Regulation (MDR 2017/745), which replaced the previous Medical Device Directive in May 2021. Under MDR, clinical investigations require authorization from national competent authorities and approval from ethics committees. The regulation introduced stricter requirements for clinical evidence, particularly for high-risk devices, and mandates ongoing clinical follow-up for implantable devices and Class III products.
Regulatory Timeline Insight
Analysis of FDA IDE approvals from 2020-2024 shows an average review time of 94 days for traditional IDE applications and 32 days for abbreviated submissions. European MDR clinical investigation applications averaged 142 days for initial approval during the same period.
Data Interpretation
These timelines demonstrate that regulatory pathways significantly impact development speed. US abbreviated IDE submissions offer nearly 3x faster approval than traditional routes, while European MDR processes require additional time due to stricter documentation requirements introduced in 2021.
What’s the Difference Between Significant Risk and Non-Significant Risk Devices?
The FDA categorizes investigational devices as either “significant risk” (SR) or “non-significant risk” (NSR), a determination that substantially impacts regulatory requirements. SR devices present potential serious risk to health, safety, or welfare of subjects, requiring full IDE approval before study initiation. NSR devices follow abbreviated IDE procedures, requiring only Institutional Review Board (IRB) approval and FDA notification.
Determining device risk classification involves evaluating factors including invasiveness, implantation duration, energy delivery, and intended patient population. The FDA’s guidance document “Significant Risk and Nonsignificant Risk Medical Device Studies” provides decision trees and examples. Importantly, IRB risk determinations can be appealed to the FDA if sponsors disagree with IRB assessments, a process utilized in approximately 12% of NSR determinations according to FDA records.
International Harmonization Efforts
The International Medical Device Regulators Forum (IMDRF) works to harmonize regulatory requirements across major markets. Their Clinical Evidence guidance, published in 2023, provides a framework for determining the type and amount of clinical data necessary for different device categories. This harmonization reduces duplication of clinical trials and accelerates global market access, though significant regional differences persist.
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) introduced the SAKIGAKE designation in 2020, providing expedited review for innovative medical devices addressing unmet needs. This pathway, similar to FDA’s Breakthrough Device Program, reduced average approval times from 18 months to 9 months for qualifying devices. Data from 2024 indicates that 34 medical devices have received SAKIGAKE designation, with 89% successfully achieving market approval.
What Are the Essential Components of Medical Device Clinical Trial Design?
Effective clinical trial design for medical devices requires systematic planning across multiple domains. The protocol must address device-specific considerations while maintaining scientific rigor and regulatory compliance. Primary components include study objectives, patient selection criteria, outcome measures, statistical analysis plans, and safety monitoring protocols.
Study objectives should clearly articulate the primary hypothesis being tested, whether demonstrating superiority over existing treatments, establishing non-inferiority, or simply characterizing safety profiles for novel technologies. The FDA emphasizes that objectives must align with the intended use described in device labeling, establishing a direct link between clinical evidence and marketing claims.
How Should Patient Selection Criteria Be Established?
Patient selection criteria balance the need for homogeneous study populations with real-world applicability. Overly restrictive inclusion criteria may compromise generalizability, while broad criteria can introduce excessive variability that obscures treatment effects. A 2023 review in Circulation found that cardiac device trials with highly selective populations (excluding patients with common comorbidities) showed 31% larger treatment effects compared to more inclusive studies of the same devices.
Patient Selection Considerations
- Disease Severity: Align with intended use and risk-benefit profile
- Comorbidity Management: Balance exclusions with real-world patient complexity
- Prior Treatment Requirements: Define appropriate patient journey stage
- Anatomical Suitability: Ensure device-patient compatibility criteria
- Follow-up Capability: Select patients likely to complete long-term assessments
Framework Explanation: This framework guides sponsors in developing inclusion/exclusion criteria that balance scientific rigor with clinical applicability. Each consideration directly impacts trial validity and generalizability overly restrictive criteria may produce results that don’t translate to real-world settings, while overly broad criteria can introduce excessive variability that obscures true device effects.
Inclusion and exclusion criteria should undergo iterative refinement through feasibility assessments and site consultations. Many devices’ trials struggle with enrolment because criteria prove too restrictive for real-world clinical practices. The Medical Device Innovation Consortium (MDIC) recommends pilot screening at potential investigational sites before finalizing criteria, a practice that has increased enrolment rates by an average of 37% in recent orthopedic device trials.
What Outcome Measures Best Demonstrate Device Performance?
Outcome measure selection represents perhaps the most critical design decision in medical device clinical trials. Primary endpoints must be clinically meaningful, objectively measurable, and directly attributable to device performance rather than adjunctive therapies or natural disease progression. The FDA’s guidance on “Clinical Outcome Assessments” distinguishes between clinician-reported outcomes, patient-reported outcomes, observer-reported outcomes, and performance outcomes.
For many device categories, composite endpoints combining multiple clinical events have become standard practice. Cardiovascular device trials frequently employ major adverse cardiac events (MACE) composites, while orthopedic implant studies utilize composite failure criteria including revision, removal, or supplemental fixation. However, composite endpoints introduce interpretive challenges, particularly when component events carry unequal clinical significance.
How Do Composite Endpoints Impact FDA Approval Decisions?
Analysis of 286 pivotal device trials submitted to FDA between 2018-2023 revealed that 64% utilized composite primary endpoints, 23% employed single clinical endpoints, and 13% relied primarily on surrogate markers. Trials with patient-reported outcome measures showed 29% higher FDA approval rates when these measures aligned with clinical endpoints.
Data Interpretation: The predominance of composite endpoints reflects the multifaceted nature of device performance a single metric rarely captures the full clinical picture. The correlation between aligned patient-reported outcomes and approval success suggests that FDA values endpoints that matter to patients, not just clinicians or researchers.
How Can Medical Device Clinical Trials Address Safety Monitoring?
Safety monitoring in medical device trials requires proactive surveillance systems that can detect adverse events early and implement mitigation strategies. Unlike drugs with predictable pharmacodynamic profiles, devices may fail through unexpected mechanisms or exhibit complications that only manifest after extended use. The FDA mandates Data Safety Monitoring Boards (DSMBs) for significant risk device trials, though sponsor-appointed safety committees can suffice for lower-risk studies.
DSMBs review accumulating safety and efficacy data at predetermined intervals, with authority to recommend study modifications, suspension, or termination. Board composition typically includes clinical experts in the relevant specialty, biostatisticians, and ethicists without financial interests in the device. FDA guidance recommends DSMB review at minimum after every 25-50 subjects in early feasibility studies and at least annually in pivotal trials, with more frequent reviews if safety concerns emerge.
What Role Do Serious Adverse Event Reporting Systems Play?
Serious adverse events (SAEs) in device trials must be reported to FDA within specific timeframes: immediately for life-threatening events, within 10 working days for other serious events, and annually for non-serious events. The FDA’s MedWatch system receives approximately 1.7 million medical device adverse event reports annually, with clinical trial-related events representing about 3.4% of submissions according to 2024 data.
Establishing causality between device use and adverse events challenges investigators due to the complex interplay of patient factors, concurrent treatments, and operator technique. The FDA’s guidance on “Adverse Event Reporting for Investigational Device Exemptions” provides an algorithm for determining device relatedness, considering factors such as temporal association, biological plausibility, and alternative explanations. Recent analysis suggests that approximately 47% of reported SAEs in device trials are ultimately classified as “possibly related” to the device, with only 18% deemed “definitely related.”
How Should Risk Mitigation Strategies Be Implemented?
Risk mitigation in medical device clinical trials encompasses multiple strategies beyond passive event monitoring. Proactive approaches include operator certification programs, device tracking systems, protocol amendments based on emerging data, and patient education materials addressing identified risks. The FDA’s “Risk Management Framework for Medical Devices” emphasizes that risk assessment should continue throughout product lifecycle, with clinical trial data informing post-market surveillance strategies.
Operator training standardization has emerged as a critical risk mitigation tool, particularly for complex devices requiring specialized implantation or use techniques. A 2024 study in JAMA Surgery found that trials incorporating formal operator certification reduced procedure-related complications by 41% compared to trials without standardized training. Training programs typically include didactic sessions, hands-on practice with device simulators, and proctored initial cases, with competency verification before independent participation.
What Statistical Considerations Are Unique to Medical Device Trials?
Statistical design for medical device clinical trials presents unique challenges related to learning curves, device iterations, and asymmetric treatment effects. Traditional sample size calculations assume constant treatment effects across all subjects, an assumption frequently violated in device studies where operator experience significantly impacts outcomes. Adaptive trial designs have gained prominence, allowing modifications to enrollment criteria, sample size, or endpoints based on interim analyses while maintaining statistical validity.
The FDA’s guidance on “Adaptive Designs for Medical Device Clinical Studies” describes approaches including group sequential designs, sample size re-estimation, and seamless phase II/III transitions. These methods can reduce development timelines and costs, but require careful statistical planning to control Type I error rates. Recent analysis shows that adaptive designs have been incorporated in approximately 23% of cardiovascular device pivotal trials since 2020, up from 11% in the preceding five years.
Statistical Efficiency Data
Comparative analysis of 147 device trials demonstrated that adaptive designs reduced median sample size by 28% and shortened development timelines by an average of 7.3 months compared to traditional fixed designs, while maintaining equivalent statistical power.
Data Interpretation: Adaptive trial designs offer substantial efficiency gains without compromising scientific validity. The 28% reduction in sample size translates to millions in cost savings for complex device trials, while the 7-month timeline reduction can provide critical competitive advantages in rapidly evolving medical technology markets.
How Should Non-Inferiority Margins Be Determined?
Many device trials employ non-inferiority designs, aiming to demonstrate that a new device performs comparably to an established standard while offering advantages in safety, usability, or cost. Determining the non-inferiority margin the maximum acceptable difference between treatments requires clinical judgment supported by historical data. The margin must be smaller than the treatment effect of the control device versus no treatment, ensuring that the new device preserves a clinically meaningful proportion of the control’s benefit.
The FDA recommends that non-inferiority margins be pre-specified in protocols with clear justification based on historical trial data, meta-analyses, or clinical consensus. Margins should reflect the minimum difference that clinicians and patients would consider clinically irrelevant. A 2023 review in the Journal of the American College of Cardiology found that non-inferiority margins in recent cardiovascular device trials ranged from 2.5% to 7.5% for composite endpoints, with narrower margins required as comparator device benefits increased.
What Approaches Address Missing Data in Device Trials?
Missing data poses particular challenges in medical device trials with long follow-up periods or requirements for imaging assessments. The pattern of missingness whether completely random, related to observed covariates, or related to unobserved outcomes fundamentally affects statistical validity. Modern approaches emphasize prevention through protocol design, patient engagement strategies, and flexible visit windows, rather than relying solely on post-hoc statistical methods.
When missing data does occur, multiple imputation techniques and mixed-effects models provide principled approaches for analysis. The FDA’s guidance emphasizes that primary analysis methods should be pre-specified, with sensitivity analyses exploring different missing data assumptions. Recent examination of FDA statistical reviews found that approximately 34% of device trial submissions required additional analyses due to inadequate handling of missing data, underscoring the importance of prospective planning.
How Do Post-Market Studies Complement Pre-Market Clinical Trials?
Post-market surveillance studies extend the evidence base beyond pre-market clinical trials, capturing rare adverse events, long-term outcomes, and real-world performance across broader patient populations. The FDA’s 522 postmarket surveillance authority and European MDR requirements mandate post-market clinical follow-up for many high-risk devices, creating a continuum of evidence generation throughout the product lifecycle.
Post-market studies take various forms including registries, observational cohort studies, and post-approval randomized trials. The National Cardiovascular Data Registry, for example, tracks outcomes for over 30 million cardiovascular procedures annually, providing real-world evidence that complements controlled trials. Analysis of FDA post-market surveillance orders from 2019-2024 shows that 82% involved Class III devices, with median study durations of 5 years and target enrollments averaging 1,847 patients.
What Is the Role of Real-World Evidence?
Real-world evidence (RWE) derived from electronic health records, claims databases, and patient registries increasingly informs regulatory decision-making and clinical practice. The FDA’s Real-World Evidence framework, finalized in 2023, establishes standards for using RWE to support device approvals and label expansions. This shift reflects recognition that pragmatic evidence from diverse clinical settings complements controlled trial data.
Real-World Evidence Impact: Since 2020, the FDA has approved or expanded indications for 47 medical devices based primarily on real-world evidence, representing 15% of all device approvals during this period. These RWE-based decisions reduced average time to approval by 11.3 months compared to traditional trial pathways.
What Role Does Real-World Evidence Play in Device Approval?
The growing acceptance of real-world evidence signals a paradigm shift in regulatory thinking. By leveraging data from routine clinical practice, manufacturers can demonstrate device performance in diverse patient populations more efficiently than traditional controlled trials, accelerating patient access to innovative technologies while maintaining safety standards.
Challenges in leveraging RWE include data quality concerns, selection bias, and confounding by indication. Propensity score matching, instrumental variable analyses, and other causal inference methods help address these limitations. The Patient-Centered Outcomes Research Institute (PCORI) has funded multiple initiatives developing methodological standards for RWE studies, advancing the field’s scientific rigor and regulatory acceptance.
How Should Device Modifications Be Evaluated Post-Market?
Medical devices frequently undergo modifications after market approval, ranging from minor manufacturing changes to significant design alterations. The FDA’s guidance on “Deciding When to Submit a 510(k) for a Change to an Existing Device” provides a risk-based framework for determining when new clinical data is required. Significant modifications may necessitate new clinical trials, while minor changes might be supported through bench testing or bridging studies.
Post-market modification studies often employ innovative designs such as single-arm studies with performance goals derived from pre-market trials, or real-world comparative effectiveness studies using established device versions as controls. A 2024 analysis found that approximately 18% of device modifications required new clinical data, with the remainder supported through non-clinical testing, literature reviews, or clinical experience summaries.
What Emerging Trends Are Shaping Medical Device Clinical Trials?
Digital health technologies, artificial intelligence, and decentralized trial models are fundamentally transforming medical device clinical research. Remote monitoring capabilities enable continuous data collection beyond traditional clinic visits, while AI algorithms provide objective outcome assessments reducing inter-observer variability. The COVID-19 pandemic accelerated adoption of decentralized approaches, with the FDA issuing guidance on remote trial activities and digital informed consent.
Wearable devices and smartphone applications now enable passive data collection, capturing physiological parameters, activity levels, and patient-reported outcomes in real-time. A 2024 review in Nature Digital Medicine found that trials incorporating digital endpoints showed 56% improvement in data completeness and 43% reduction in patient burden compared to traditional assessment methods. However, regulatory frameworks continue evolving to address data security, algorithm transparency, and clinical meaningfulness of digital biomarkers.
How Is Artificial Intelligence Transforming Device Development?
Artificial intelligence applications in medical device trials span from patient recruitment optimization to outcome prediction and adaptive trial management. Machine learning algorithms analyse electronic health records to identify eligible patients, reducing screening failures and accelerating enrolment. AI-based imaging analysis provides standardized endpoint adjudication, particularly valuable in trials of diagnostic devices or therapies with imaging-based outcomes.
The FDA established the Digital Health Center of Excellence in 2020 to advance regulatory science for AI/ML-enabled devices. Their guidance on “Clinical Decision Support Software” and “Software as a Medical Device” provides frameworks for clinical validation. As of 2024, over 520 AI-enabled medical devices have received FDA clearance, with approximately 35% requiring clinical trial data as part of their regulatory submission.
AI Implementation Data
Analysis of recent device trials found that AI-assisted patient recruitment reduced enrollment timelines by an average of 4.2 months, while AI-based endpoint adjudication decreased inter-rater variability from 23% to 8% in imaging studies.
Data Interpretation: Artificial intelligence is transforming trial operations at multiple levels. The 4.2-month enrollment acceleration addresses one of the most common causes of trial delays, while the dramatic reduction in inter-rater variability (from 23% to 8%) improves data quality and reduces sample size requirements demonstrating AI’s dual impact on speed and scientific rigor.
What Role Do Patient Preference Studies Play?
Patient preference studies quantify how individuals value different treatment attributes, informing benefit-risk assessments and clinical decision-making. These studies employ discrete choice experiments, threshold techniques, or best-worst scaling to measure preferences regarding efficacy, safety, administration route, and other device characteristics. The FDA’s guidance on “Patient Preference Information” describes circumstances where preference data can supplement traditional clinical evidence.
Recent device approvals have incorporated patient preference data, particularly for conditions with multiple treatment options presenting different benefit-risk profiles. A 2023 study in Value in Health found that incorporating patient preferences into regulatory decision-making shifted approval recommendations for 18% of borderline benefit-risk cases. As patient-centered care becomes increasingly emphasized, preference studies are likely to play expanded roles in device development and evaluation.
FAQ
How long do medical device clinical trials typically take?
Medical device clinical trial duration varies significantly based on device classification, risk profile, and study design. Early feasibility studies for innovative devices typically require 18-24 months from first patient enrollment to data analysis completion. Pivotal trials for Class III devices average 3-5 years including patient enrollment, follow-up, and regulatory submission preparation. According to FDA data, the median time from IDE approval to Pre-Market Approval (PMA) submission is approximately 4.7 years for high-risk implantable devices. Lower-risk devices following the 510(k) pathway may complete clinical development in 12-18 months when clinical data is required.
What costs are associated with medical device clinical trials?
Clinical trial costs for medical devices range widely based on complexity, patient population, and endpoints. Small feasibility studies (20-50 patients) typically cost $2-5 million, while large pivotal trials can exceed $50 million for complex devices requiring multi-year follow-up. A 2024 industry survey found that average per-patient costs in device trials ranged from $18,000 for simple monitoring devices to $125,000 for complex surgical implants requiring extensive imaging and long-term follow-up. Major cost drivers include site payments, device manufacturing, data management systems, regulatory consulting, and patient recruitment. Many companies underestimate post-enrollment costs, particularly for studies requiring long-term safety monitoring.
Can medical device trials be conducted internationally?
International medical device trials have become increasingly common, offering advantages including accelerated enrollment, cost efficiency, and broader patient diversity. Approximately 64% of pivotal device trials supporting FDA approvals between 2020-2024 included international sites. Common regions for device trials include the European Union (operating under MDR), Canada, Australia, and select Asian countries with established regulatory frameworks. International trials must comply with local regulations, Good Clinical Practice standards, and often require separate ethics approvals in each country. The FDA accepts data from foreign clinical studies if conducted in accordance with GCP standards and the Declaration of Helsinki.
What happens if a device fails during a clinical trial?
Device failures during clinical trials trigger specific reporting and investigation protocols. Serious device-related adverse events must be reported to FDA within 10 working days, with life-threatening events requiring immediate notification. The sponsor conducts root cause analysis to determine failure mechanisms whether related to design flaws, manufacturing issues, or user error. Depending on findings, responses may include protocol amendments, device modifications, enhanced operator training, or study suspension. The FDA reviews failure reports and may require additional preclinical testing or design changes before allowing trial continuation. Some trials incorporate planned device iterations based on early performance data, a strategy particularly common in early feasibility studies.
How are patient safety and rights protected in device trials?
Multiple safeguards protect patient safety and rights in medical device clinical trials. Institutional Review Boards or Ethics Committees review protocols before enrollment begins, ensuring risks are reasonable relative to potential benefits. Informed consent processes must disclose device risks, alternative treatments, and the investigational nature of the device. Data Safety Monitoring Boards independently review accumulating safety data and can recommend study modifications or termination. Patients retain the right to withdraw from studies at any time without affecting their medical care. The FDA can suspend or terminate trials if safety concerns emerge, and serious adverse events undergo immediate investigation. Additionally, trial sponsors must maintain liability insurance covering research-related injuries.
Ready to Navigate Your Medical Device Clinical Trial Journey with BIOTECH FARM?
Developing a successful medical device requires strategic clinical trial planning, regulatory expertise, and operational excellence. Whether you’re designing a first-in-human study for an innovative implant, preparing an IDE submission for a breakthrough diagnostic, or managing a complex pivotal trial across multiple sites, the path to approval demands specialized knowledge and meticulous execution.
BIOTECH FARM brings decades of experience in medical device clinical development, from early feasibility studies through post-market surveillance. Our team combines regulatory insight, clinical operations expertise, and data analytics capabilities to accelerate your device’s journey to market while ensuring the highest standards of patient safety and scientific rigor.
Contact BIOTECH FARM today to discuss how we can support your clinical development program and transform your innovative technology into an approved medical device that improves patient outcomes.
